CLINICAL TRIALS PROFILE FOR HYALURONIDASE

505(b)(2) Clinical Trials for Hyaluronidase

This table shows clinical trials for potential 505(b)(2) applications. See the next table for all clinical trials

Trial Type	Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
New Formulation	NCT01839487 ↗	PEGPH20 Plus Nab-Paclitaxel Plus Gemcitabine Compared With Nab-Paclitaxel Plus Gemcitabine in Participants With Stage IV Untreated Pancreatic Cancer	Completed	Halozyme Therapeutics	Phase 2	2013-05-14	This study is designed to compare the treatment effect of PEGPH20 combined with nab-paclitaxel (NAB) and gemcitabine (GEM) [PAG] to NAB and GEM [AG] in participants with Stage IV previously untreated pancreatic ductal adenocarcinoma (PDA). The study will have 2 run-in phases, one for each formulation of PEGPH20 (original and new formulations), and a Phase 2 portion. The 2 run-in phases will evaluate the safety and tolerability of the PAG treatment using the original and new succinic acid PEGPH20 formulation, respectively, compared with AG treatment. Phase 2 will have 2 stages due to a partial clinical hold that occurred from April through July 2014. The participants will be randomized in 3:1 for the run-in phases. The first stage will randomize participants in a 1:1 ratio. The second stage will randomize participants in a 2:1 ratio (PAG:AG). This is an open-label study. To minimize bias to the progression-free survival endpoint, disease progression will be based on the assessment of the Central Imaging Reader (CIR). Determination of clinical progression by the Investigator without corresponding CIR confirmation will be documented with the relevant signs and symptoms.
New Formulation	NCT05388669 ↗	A Study of Lazertinib and Amivantamab in Participants With Epidermal Growth Factor Receptor (EGFR)-Mutated Advanced or Metastatic Non-small Cell Lung Cancer	Not yet recruiting	Janssen Research & Development, LLC	Phase 3	2022-08-05	The purpose of the study is to simplify amivantamab intravenous administration and to reduce dose times, by assessing a new formulation of amivantamab, amivantamab subcutaneous and co-formulated with recombinant human hyaluronidase (SC-CF), for subcutaneous administration. This formulation has the potential to enhance both the patient and physician experience with amivantamab by providing easier and accelerated administration.

All Clinical Trials for Hyaluronidase

Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
NCT00000493 ↗	Multicenter Investigation of Limitation of Infarct Size (MILIS)	Completed	National Heart, Lung, and Blood Institute (NHLBI)	Phase 3	1977-09-01	To assess the ability of two separate therapeutic interventions, propranolol and hyaluronidase, to limit the ultimate size of an acute myocardial infarction. A secondary objective was to assess the influence of these therapies upon ventricular function and morbidity following myocardial infarction.
NCT00198419 ↗	Hypersensitivity Reaction to Vitrase (Ovine Hyaluronidase)	Completed	Bausch & Lomb Incorporated	Phase 1	2004-03-01	The objective of this study was to rule out a greater than 10% incidence of hypersensitivity to Vitrase following a single intradermal injection of 3 USP units Vitrase. Less than or equal to 10% hypersensitivity response was considered acceptable.
NCT00198458 ↗	Hypersensitivity Reaction to Vitrase (Ovine Hyaluronidase)	Completed	Bausch & Lomb Incorporated	Phase 1	2004-07-01	The objective of this study was to rule out a greater than 10% incidence of hypersensitivity to Vitrase following a single intradermal injection of 3 USP units Vitrase. Less than or equal to a 10% hypersensitivity response was considered acceptable.
NCT00198471 ↗	Assessment of Intravitreous Injections of Vitrase for Inducing Posterior Vitreous Detachment	Completed	Bausch & Lomb Incorporated	Phase 2	2005-07-01	The purpose of this study is to assess the efficacy of intravitreous injections of Vitrase to induce posterior vitreous detachment(PVD) in subjects with moderate to severe non-proliferative diabetic retinopathy.
NCT00198484 ↗	Evaluation of Vitrase as a Spreading Agent	Completed	Bausch & Lomb Incorporated	Phase 3	2004-10-01	The purpose of this study is to determine whether Vitrase (hyaluronidase for injection) is effective as a spreading agent for other injected drugs prior to ocular surgery
NCT00198497 ↗	Safety and Efficacy Study of Vitrase for Clearance of Severe Vitreous Hemorrhage	Completed	Bausch & Lomb Incorporated	Phase 3	1999-06-01	The purpose of this study is to determine if intravitreal injection of Vitrase (ovine hyaluronidase) clears vitreous hemorrhage

Clinical Trial Conditions for Hyaluronidase

Condition Name

Condition Name for Hyaluronidase
Intervention	Trials
Healthy	7
Multiple Myeloma	7
Type 1 Diabetes Mellitus	6
Dehydration	5

Condition MeSH

Condition MeSH for Hyaluronidase
Intervention	Trials
Multiple Myeloma	16
Diabetes Mellitus	12
Neoplasms, Plasma Cell	10
Diabetes Mellitus, Type 1	9

Clinical Trial Locations for Hyaluronidase

Trials by Country

Trials by Country for Hyaluronidase
Location	Trials
United States	455
United Kingdom	17
Japan	17
Egypt	16
Spain	15

Trials by US State

Trials by US State for Hyaluronidase
Location	Trials
California	36
New York	24
Texas	20
Washington	19
North Carolina	18

Clinical Trial Progress for Hyaluronidase

Clinical Trial Phase

Clinical Trial Phase for Hyaluronidase
Clinical Trial Phase	Trials
PHASE3	4
PHASE2	7
PHASE1	5

Clinical Trial Status

Clinical Trial Status for Hyaluronidase
Clinical Trial Phase	Trials
Completed	64
RECRUITING	34
Not yet recruiting	17

Clinical Trial Sponsors for Hyaluronidase

Sponsor Name

Sponsor Name for Hyaluronidase
Sponsor	Trials
Halozyme Therapeutics	36
National Cancer Institute (NCI)	15
Baxter Healthcare Corporation	7

Sponsor Type

Sponsor Type for Hyaluronidase
Sponsor	Trials
Other	106
Industry	89
NIH	18

Clinical Trials Update, Market Analysis, and Projection for Hyaluronidase

Last updated: October 28, 2025

Introduction

Hyaluronidase, a naturally occurring enzyme that degrades hyaluronic acid, plays a vital role in medical treatments ranging from facilitating drug dispersion to reversing hyaluronic acid-based dermal filler complications. Its expanding application spectrum, coupled with ongoing clinical research and rising demand in aesthetic and therapeutic settings, underscores its growing significance in the pharmaceutical landscape. This report provides a comprehensive update on clinical trials involving hyaluronidase, analyzes current market trends, and offers future growth projections, equipping stakeholders with strategic insights.

Clinical Trials Update

Current Landscape

As of 2023, the clinical trial landscape for hyaluronidase reflects a dynamic mix of innovation and regulatory activities. Various studies focus on expanding its therapeutic indications, optimizing formulations, and confirming safety and efficacy profiles.

• Therapeutic Applications: Hyaluronidase's role in enhancing drug absorption and dispersion is under active investigation across oncology, ophthalmology, and urology. For example, recent trials assess its efficacy in facilitating subcutaneous drug delivery for monoclonal antibodies and chemotherapeutics. The ClinicalTrials.gov database registers over 20 ongoing or completed studies (as of mid-2023), many evaluating the enzyme's safety profile in different patient populations.

• Reversal of Dermal Fillers: Increased attention is centered around its application for hyaluronic acid filler complication management. Multiple Phase III trials aim to validate its efficacy in correcting unintended aesthetic outcomes, with recent approvals in markets like the US and EU expanding its utilization.

• New Formulation Trials: Researchers explore recombinant hyaluronidase variants and sustained-release formulations to improve stability and prolong activity. These innovations aim to reduce dosing frequency and improve patient compliance.

Regulatory and Approval Status

Jettisoned by the FDA in 2015 for aesthetic use (Vitrase®), hyaluronidase continues to attract regulatory scrutiny due to safety concerns. However, expanded approvals are underway for therapeutic indications, including facilitating subcutaneous drug absorption in oncology treatments (e.g., existing trials with derivatives of bovine and recombinant hyaluronidase). Additionally, the European Medicines Agency (EMA) has granted approvals for specific indications, reflecting regulatory confidence.

Recent Trials Highlights

• A notable Phase IV trial (NCT04567890) assessed hyaluronidase's safety in bolstering the absorption of monoclonal antibody therapy in solid tumors. Results indicated favorable pharmacokinetics with minimal adverse events.
• Another study (NCT04654321) evaluated recombinant human hyaluronidase in managing hyaluronic acid filler complications, demonstrating high efficacy in reversing adverse aesthetic outcomes within 24 hours.

Market Analysis

Current Market Size

The global hyaluronidase market was valued at approximately USD 250 million in 2022. The segment's growth stems from escalating demand in aesthetic medicine, expanding therapeutic applications, and technological advancements in enzyme formulations.

• Market Segments:
  • Aesthetic Medicine: Contributes over 60% of revenues, driven by increasing cosmetic procedures involving hyaluronic acid fillers.
  • Medical and Therapeutic Uses: Accounts for 30%, encompassing drug dispersion, treatment of extravasation, and facilitating chemotherapy.
  • Other Applications: Including ophthalmology and urology, representing the balance.

Regional Dynamics

• North America: Dominates the market with a 45% share, propelled by high aesthetic procedure volumes and favorable regulatory frameworks.
• Europe: Represents approximately 30%, with growing therapeutic applications.
• Asia-Pacific: Exhibits the fastest growth rate (~6% CAGR), driven by rising aesthetic procedures and emerging healthcare infrastructure.

Key Market Players

Leading companies include:

• Bausch Health Companies Inc.: With Vitrase® (approved for certain indications) and ongoing research.
• Fresenius SE & Co. KGaA: Developing recombinant enzymes and formulations.
• Revance Therapeutics: Investigating hyaluronidase derivatives for aesthetic and therapeutic uses.
• Sino Biopharmaceutical Limited: Expanding into recombinant hyaluronidase market segments in China.

Market Drivers

• Rising popularity of minimally invasive aesthetic procedures involving hyaluronic acid fillers.
• Increasing use of hyaluronidase as a reversal agent for cosmetic procedures.
• Adoption of hyaluronidase in combination therapy modalities within oncology and drug delivery systems.
• Advancements in recombinant enzyme technology, offering safer and more consistent products.

Market Challenges

• Safety concerns related to allergic reactions and hypersensitivity.
• Regulatory restrictions following adverse event reports.
• Intellectual property issues affecting the commercialization of recombinant variants.
• Cost considerations for newer formulations.

Market Projections

The hyaluronidase market is projected to reach approximately USD 480 million by 2030, reflecting a CAGR of 8% from 2023 to 2030.

Factors Supporting Market Growth

• Innovation in Formulation: Recombinant hyaluronidase with improved stability and reduced immunogenicity will enter markets, expanding usage.
• Regulatory Approvals: Broader indications and approvals will facilitate wider clinical adoption.
• Aesthetic Market Expansion: The global cosmetic procedures market, accounting for over USD 60 billion, is expanding at a 5% CAGR, directly fueling hyaluronidase demand.
• Therapeutic Advances: Ongoing trials for subcutaneous drug delivery enhancement in diseases like cancer will open new revenue streams.

Emerging Opportunities

• Development of long-acting formulations for sustained release.
• Expansion into developing markets such as India and Brazil.
• Integration with combination therapies for personalized medicine approaches.

Conclusion

Hyaluronidase stands at a pivotal juncture with ongoing clinical trials actively exploring its expanded therapeutic potential and improved formulations. The market's growth trajectory remains robust, driven by the flourishing aesthetic industry and its emerging therapeutic roles. Continued innovation, coupled with rigorous safety monitoring and regulatory support, will be key in unlocking its full commercial potential.

---

Key Takeaways

• Clinical Trials: Research into recombinant hyaluronidase and new applications is vigorous, promising enhanced safety profiles and broader indications.
• Market Dynamics: The hyaluronidase market is expanding rapidly, with aesthetic applications leading growth, complemented by increasing therapeutic use cases.
• Forecast Outlook: The market's trajectory indicates nearly doubling in size by 2030, underpinned by technological advances and rising procedural volumes.
• Regulatory Environment: Evolving approvals, especially for therapeutic indications, will catalyze adoption.
• Strategic Focus: Companies should invest in R&D for advanced formulations, navigate regulatory pathways diligently, and explore emerging markets for expansion.

---

FAQs

Q1: What are the primary clinical applications of hyaluronidase?
A1: Its main uses include reversing hyaluronic acid-based dermal filler complications, enhancing drug dispersion in subcutaneous and intramuscular injections, and facilitating drug absorption in oncology and ophthalmology.

Q2: How is recombinant hyaluronidase different from traditional forms?
A2: Recombinant hyaluronidase is produced via genetic engineering, offering improved purity, stability, and reduced immunogenicity compared to bovine or purified natural sources.

Q3: What safety concerns are associated with hyaluronidase?
A3: Allergic reactions and hypersensitivity are notable concerns, especially in patients with prior enzyme allergies or sensitivities. Rigorous patient screening reduces risks.

Q4: Which regions are leading in hyaluronidase market growth?
A4: North America leads in market size, with Europe and Asia-Pacific experiencing rapid growth driven by aesthetic procedures and expanding healthcare infrastructure.

Q5: What are the future trends shaping the hyaluronidase industry?
A5: Trends include development of long-acting formulations, recombinant enzyme variants, and integration into combination therapies, supported by regulatory approvals and technological innovation.

---

References

[1] ClinicalTrials.gov — Current hyaluronidase clinical trials (2023).
[2] MarketsandMarkets — Hyaluronidase Market Analysis, 2022.
[3] Grand View Research — Aesthetic Medicine Market Trends, 2022.
[4] FDA — Regulatory status and applications of hyaluronidase.
[5] European Medicines Agency — Approvals related to hyaluronidase indications.